Intellectual Product

Trump Announces Sweeping Cost Cuts on Lilly and Novo Weight Loss Drugs in Exchange for Medicare Coverage

21 hours ago talkbio0Tagged drug price, Eli Lilly ; Novo Nordisk, Glucagon-Like Peptide 1, Medicaid, Medicare, Prices, Transplant Registry Unified Management Program, Wegovy, Weight-Loss Agents, Zepbound

Trump; Eli Lilly; Novo Nordisk; weight loss drugs; GLP-1; Medicare; Medicaid; Wegovy; Zepbound; price cuts; drug pricing deal

Vera Therapeutics Announces Full Phase 3 Win for Atacicept in Kidney Disease, Prepares FDA Filing by Year’s End

1 day ago talkbio0Tagged asparagine, Atacicept, autoimmune kidney disease, Blackfoot language, File (record), IGA, IGA Glomerulonephritis, Kidney, Phase 3 trial, Proteinuria, Submission, United States Food and Drug Administration, UPCR, Vera Therapeutics

Vera Therapeutics; atacicept; Phase 3 trial; IgA nephropathy; proteinuria reduction; UPCR; FDA filing; BLA submission; ASN Kidney Week 2025; autoimmune kidney disease

TriNetX Achieves Record as the Most Cited Real-World Electronic Health Record Dataset in Peer-Reviewed Research

2 days ago talkbio0Tagged Citation, Clinical Trials, Data Analytics, Electronic Health Records, global network, Medical Research activity, Peer-Reviewed Research, Rare Diseases, real-world data, TriNetX

TriNetX; real-world data; electronic health records; peer-reviewed research; citations; medical research; data analytics; global network; rare disease; clinical trials

Arena BioWorks Shuts Down After Investors Withdraw Support for Bold Biotech Model

2 days ago talkbio0Tagged Arena BioWorks, Biomedical Research, concerns, Funding, funding environment, Industry, investor, layoffs, Policy, shutdown, Uncertainty

Arena BioWorks; biotech shutdown; policy uncertainty; funding environment; biomedical research; $500 million funding; layoffs; biotech industry; investor concerns

Closed Loop Medicine Secures Additional Key GLP-1 Patent for Its AI-Based Dosing Platform: Powering Personalized, Direct-to-Patient Therapies

3 days ago talkbio0Tagged adaptive dosing, AI-based, Closed Loop Medicine, dosing, Glucagon-Like Peptide 1, incretin drugs, Legal patent, personalized therapies, semaglutide, WeDosify

Closed Loop Medicine; GLP-1; patent; AI-based dosing; personalized therapies; semaglutide; incretin drugs; WeDosify; adaptive dosing; direct-to-patient

Recent News: Live at 11 a.m. ET – M&A, FDA, MFN and Collaboration with FT

4 days ago talkbio0Tagged Acquisitions, Drug Approval, Economics, Financial Times, Live - Specimen Condition, M&A, mergers, MFN, News [Publication Type], United States Food and Drug Administration

M&A; FDA; MFN; Financial Times; mergers and acquisitions; drug approval; economics; live news

Spotlight On: VC Deal Flow – October’s Haul Sets 2025 up to Run Rings Around Previous Year

4 days ago talkbio0Tagged 2025, Deal Flow, Exit activity, funding rounds, Investments, Megadeals, October, Sector, Trail Making Test, Unicorn births, venture capital

Venture Capital; Deal Flow; 2025; October Funding; AI investment; Megadeals; Exit activity; TMT sector; Funding rounds; Unicorn births

Viking Therapeutics to Highlight VK2735 Clinical Data at ObesityWeek 2025

1 week ago talkbio0Tagged Clinical Data, Clinical Trials, GLP-1/GIP Dual Agonist, Metabolic Syndrome X, Obesity, ObesityWeek 2025, Prediabetes syndrome, VANQUISH-1, venture, Viking Therapeutics, VK2735

Viking Therapeutics; VK2735; ObesityWeek 2025; VENTURE trial; VANQUISH-1 trial; GLP-1/GIP dual agonist; clinical data; obesity; prediabetes; metabolic syndrome

BridgeBio Shifts Filing Plans After Phase 3 Success in Rare Disease Drug BBP-418

2 weeks ago talkbio0Tagged Acoramidis, Approved, BBP-418, Biological Markers, BridgeBio, commercial, disease drug, File (record), Infrequent, Limb-girdle muscular dystrophy type 2A, NDA, New Drug Application, Phase 3 success, Ribitol, United States Food and Drug Administration

BridgeBio; BBP-418; Phase 3 success; limb-girdle muscular dystrophy type 2I/R9; FDA filing; rare disease drug; NDA (New Drug Application); ribitol; full approval; biomarker; acoramidis; commercial strategy

FDA Publishes New Filing Checklists to Prevent Drug Submission Delays

2 weeks ago talkbio0Tagged Abbreviated New Drug Application, Complete Response Letters, drug application, filing checklist, New Drug Application, regulatory guidance, submission delays, United States Food and Drug Administration

FDA; filing checklist; drug application; submission delays; New Drug Application (NDA); Abbreviated New Drug Application (ANDA); Complete Response Letters; regulatory guidance